Peritoneal mesothelioma is a form of cancer affecting the lining of the stomach (the peritoneum). It is caused by the ingestion of asbestos fibers.
What is Peritoneal Mesothelioma?
How Is Peritoneal Mesothelioma Treated?
This is the only surgical option available to those with a peritoneal diagnosis. Luckily, this surgery has high success rates as it is also used in other abdominal malignancies.
This is the most common treatment method used for peritoneal mesothelioma. It is sometimes administered directly to the abdomen during surgery.
This is typically the least invasive treatment option for peritoneal patients. Radiation may be delivered during surgery as well.
- Abdominal Pain
- Loss of Appetite
- Blood Clots
- Fluid Buildup (Ascites)
- Abdominal Swelling
- Fever or Sweating
- Tissue Lumps in the Abdomen
- Bowel Problems
In most cases, peritoneal mesothelioma does not spread to the lungs. It has been shown to spread to the other abdominal areas, such as ovaries, liver, or intestines.This metastasis often causes it to become discovered and sometimes, misdiagnosed. Symptoms of stomach pains or ascites sometimes may result in a misdiagnosis of hernias or a simple stomach ache.
How Does Peritoneal Mesothelioma Develop?
1Asbestos fibers are ingested and lodge into the lining of the abdomen (peritoneum).
2The body attempts to filter and remove these fibers, but sometimes the fibers attach to the peritoneum.
3Scar tissue builds up as a response to the body’s fight against the irritation of the fibers and can result in genetic cell damage. This can cause unchecked cell division and the formation of a malignant tumor.
Doctors may also use a technique called peritoneoscopy. A surgeon make a small incision on the patients abdomen and use a small camera to explore the abdomen. There is also a tool on the camera that helps to extract tissue on the peritoneum to test for mesothelioma.
Generally, in stage one, the mesothelioma is centralized in the abdomen and is more than likely able to be entirely removed. As it progresses to stage 2, the mesothelioma may spread more but is still contained in the peritoneum. In the third stage, it begins to metastasize to other organs, such as the liver and colon. In the final stage, stage 4, the mesothelioma has spread to other organs.
Patients in the later stages may receive palliative treatments, like radiation or chemotherapy. Another palliative treatment option may be a paracentesis to drain the fluid buildup in the abdomen.
The most successful treatment conducted has been the combination of cytoreduction surgery and HIPEC (hyperthermic intraperitoneal chemotherapy). The cytoreduction removes most of the cancerous tumor and HIPEC has been shown to kill the remaining cells.
Find doctors who can perform this procedure using our free Doctor Match program.
Cytoreduction is also referred to as “debulking.” The goal of cytoreduction is to remove as much of the tumor as possible, if not all of it. It is often not possible to remove the entire tumor. The peritoneum (lining of the abdomen) is completely removed and is usually performed in patients with stage 1 or 2 peritoneal mesothelioma.
It is also performed for other abdominal malignancies, so it is performed widely. Cytoreduction recovery can take anywhere from 7 to 13 days. One study showed a majority of patients experiencing nausea up to 13 days after their surgery. Regular activities, such as eating, drinking, re-gaining bowel functions, and mobilization were re-established within 11 days after the cytoreduction and HIPEC.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Hyperthermic Intraperitneal Chemotherapy is also known as HIPEC treatment. HIPEC is used in patients who have cancers of the abdomen. This high dose of chemotherapy removes any remaining mesothelioma cells left after a cytoreduction surgery. HIPEC is a heated and sterilized chemotherapy treatment.
The side effects of this chemotherapy are less than those of regularly administered chemotherapy. At the end of the 60-90 minutes, the chemotherapy is washed out of the body.
- Also referred to as “hot chemo”.
- Usually done after cytoreduction.
- Administered both during surgery (most effective) and after using an abdominal catheter.
Peritoneal mesothelioma patients in the later stages may receive chemotherapy for palliative purposes. Patients may be given a combination of Alimta and cisplatin, the same treatment given to pleural patients. Studies are also being done on the effectiveness of the drugs vinorelbine and gemcitabine in combination with cisplatin.
A recent case in 2009 shows promise with the combination of two popular chemotherapy drugs in patients with peritoneal mesothelioma. A patient went in for an unrelated procedure and which signs of peritoneal mesothelioma were found. The patient was given the combination of Alimta (500 mg) and cisplatin (80 mg).
After the first six cycles all signs and markers of the peritoneal mesothelioma were gone. Six months later, CT scans showed no changes or reoccurrence regarding the mesothelioma. After 4 years, the patient is alive with no signs of disease progression.
Studies show the normal survival rate of patients with peritoneal mesothelioma is around 7.6 months if they do not receive chemotherapy. Forty-one percent of patients who were given the combination experienced improvement, while 17% showed satisfactory results with cisplatin alone.
For many peritoneal mesothelioma patients, radiation is not usually effective. It may shrink tumors before or after a cytoreduction. However, there have been no cases reported of complete eradication by solely using radiation. A mesothelioma specialist can determine if radiation is right for the patient based on their specific diagnosis.
Although there are similarities between pleural and peritoneal mesothelioma, the treatment options differ. The median survival time for patients who have not had the cytoreductive surgery is about a year; however, in patients who have had the surgery, survival grows up to five years.
Learn how mesothelioma survivors beat the odds in our free Mesothelioma Survivors Guide.